You just read:

FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events

News provided by

Amgen

Jul 27, 2017, 17:49 ET